Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany

Young adults (YA) represent a minority among recipients of allogeneic haematopoietic stem cell transplantation (HSCT). In order to describe the outcome of YA following HSCT in Germany, 9299 patients who were registered with the German Registry for Stem Cell Transplantation were included in this retrospective analysis of the years 1998–2019. The impact of the variables, such as patient age and sex, sex differences, stem cell source, donor type, conditioning, year of HSCT, the diagnosis, and the achieved remission status were tested in univariable and multivariable analysis for overall, event‐free and relapse‐free survival as well as for the cumulative incidences of non‐relapse and therapy‐related mortality. Altogether, the outcome of YA after HSCT improved over time and was determined by the underlying disease, the age at disease onset, stem cell source, and donor type. Patients were most likely to die from relapse, and survival of HSCT recipients after 10 years was reduced by more than half in comparison to the general population of YA. Deeper understanding of modifiable risk factors may be gained by studies comparing the outcome of YA post‐HSCT with that of children, adolescents and elderly patients. A deliberate and strong patient selection may further improve mortality rates.

[1]  M. Pasquini,et al.  Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. , 2022, Transplantation and cellular therapy.

[2]  J. Hicks,et al.  Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 Decades: A Blood or Marrow Transplant Survivor Study Report. , 2021, JAMA oncology.

[3]  P. Chevallier,et al.  Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC) , 2021, Journal of Cancer Research and Clinical Oncology.

[4]  N. Kröger,et al.  Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021? , 2021, Haematologica.

[5]  C. Bokemeyer,et al.  Long-Term Follow-Up of Children, Adolescents, and Young Adult Cancer Survivors , 2021, Oncology Research and Treatment.

[6]  S. Montoto,et al.  How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. , 2020, Blood advances.

[7]  S. Gadalla,et al.  Comparison of total body irradiation versus non-total body irradiation containing regimens for de novo acute myeloid leukemia in children , 2020, Haematologica.

[8]  J. Liesveld,et al.  Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. , 2020, Blood advances.

[9]  M. Sorror,et al.  Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts , 2020, Annals of Internal Medicine.

[10]  S. Bhatia Cause-specific late mortality after allogeneic stem cell transplantation. , 2019, Hematology. American Society of Hematology. Education Program.

[11]  K. Geue,et al.  Cancer-specific distress, supportive care needs and satisfaction with psychosocial care in young adult cancer survivors. , 2019, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[12]  J. Finke,et al.  Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia , 2019, Bone Marrow Transplantation.

[13]  H. Ogawa,et al.  High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation. , 2019, Blood advances.

[14]  P. Mehta,et al.  Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  A. Shimoni,et al.  Second Malignancies after Hematopoietic Stem Cell Transplantation , 2018, Current Treatment Options in Oncology.

[16]  N. Majhail Long-term complications after hematopoietic cell transplantation. , 2017, Hematology/oncology and stem cell therapy.

[17]  P. Herzberg,et al.  Physical and psychosocial aspects of adolescent and young adults after allogeneic hematopoietic stem-cell transplantation: results from a prospective multicenter trial , 2017, Journal of Cancer Research and Clinical Oncology.

[18]  Milena Maria Maule,et al.  Survival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5. , 2016, The Lancet. Oncology.

[19]  J. Rowe,et al.  Acute Myeloid Leukemia in Adolescents and Young Adults: Challenging Aspects , 2014, Acta Haematologica.

[20]  Martha Askins,et al.  Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults , 2014, Acta Haematologica.

[21]  W. Wood,et al.  Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic leukemia. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  M. Verneris,et al.  Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation , 2014, Bone Marrow Transplantation.

[23]  J. Wagner,et al.  Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  S. Iacobelli Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation , 2013, Bone Marrow Transplantation.

[25]  W. Wood,et al.  Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  A. Velardi,et al.  The EBMT activity survey: 1990–2010 , 2012, Bone Marrow Transplantation.

[27]  D. Friedman,et al.  Cardiovascular Hospitalizations and Mortality Among Recipients of Hematopoietic Stem Cell Transplantation , 2011, Annals of Internal Medicine.

[28]  W. Wood,et al.  Malignant hematologic diseases in adolescents and young adults. , 2011, Blood.

[29]  Michael Boeckh,et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.

[30]  S. Siegel,et al.  Adolescent and young adult oncology training for health professionals: a position statement. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Vyas,et al.  Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia , 2010, Haematologica.

[32]  A. Gratwohl,et al.  Current role of stem cell transplantation in chronic myeloid leukaemia. , 2009, Best practice & research. Clinical haematology.

[33]  H. Deeg,et al.  Solid cancers after allogeneic hematopoietic cell transplantation. , 2009, Blood.

[34]  F. Aversa,et al.  Competing risk analysis using R: an easy guide for clinicians , 2007, Bone Marrow Transplantation.

[35]  M. Hudson,et al.  Long‐term Complications Following Childhood and Adolescent Cancer: Foundations for Providing Risk‐based Health Care for Survivors , 2004, CA: a cancer journal for clinicians.

[36]  D. Blaise,et al.  Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Bleyer,et al.  Increased risk of second malignant neoplasms in adolescents and young adults with cancer , 2016, Cancer.

[38]  J. Wagner,et al.  Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.